Please assess the completion status of the following clinical trial:

Trial Title: High Dose Vitamin D Supplementation in Children With Sickle Cell Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* children with SCD (HbSS, hemoglobin sickle beta zero (HbSβ0) thalassemia genotype), aged ≤ 18 years old, male or female study participants who were at a steady state (≥ one month from blood transfusion and ≥ 14 days from any acute sickle complication as hospitalization for Vaso occlusive crisis (VOC) or acute chest syndrome (ACS)), stable Hb level near their usual baseline and stable dose of Hydroxyurea (HÚ) mg/kg for at least 90 days prior to enrollment.~* A control group of 42 healthy age and sex-matching children~Exclusion Criteria:~* SCD patients who are on chronic blood transfusion therapy~* Comorbid chronic conditions~* Use of medications known to interfere with calcium or vitamin D absorption or metabolism~* Known hypercalcemia or vitamin D hypersensitivity~* Use of vitamin D therapy to treat vitamin D deficiency or rickets~* Urolithiasis, liver or renal impairment, and malabsorption disorders.~* Obese children with body mass index (BMI) \> 85th percentile for age and sex

- Gender: ALL
- Minimum Age: None
- Maximum Age: 18 Years
- Healthy Volunteers: t

Study Arms:
- Oral vitamin D3 (Type: EXPERIMENTAL): Monthly oral vitamin D3 dose (100,000 IU,150,000 IU, and 200,000 IU)

Based on this trial design, predict the completion outcome and termination type (if applicable).